Combination chemotherapy with docetaxel and irinotecan in metastatic malignant melanoma.

Abstract

Aim: The aim of the current trial was to assess the efficacy and toxicity of 3-weekly intravenous docetaxel and irinotecan in the treatment of patients with metastatic malignant melanoma.